NYSE$AMN
AMN Healthcare Services Inc. · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
AMN Healthcare's Q2 2020 financial results were announced, showing revenue growth and adaptability amidst the COVID-19 pandemic.
AMN Healthcare reported a 14% increase in revenue to $608 million for Q2 2020. The company's adjusted EPS was $0.83, and they reduced debt by $127 million, achieving a leverage ratio of 2.7 to 1.
- AMN team members and healthcare professionals played a crucial role in caring for COVID-19 patients.
- The company increased diversity, inclusion, equity, and equality actions.
- Q2 financial results exceeded expectations, driven by travel nurse staffing and the recovery of Stratus Video.
- Operating cash flow was $77 million, enabling debt reduction.
Headline financials
Revenue & EPS history
AMN Healthcare · Revenue · Quarterly
$608M
Revenue by segment
AMN Healthcare · $608M total across 3 segments · Q2 2020
- Nurse & Allied Solutions$444M+20.8%73.1%
- Physician & Leadership$109M-23.7%17.9%
- Technology & Workforce$55.3M+123.4%9.1%
Forward guidance
The company projects consolidated third quarter revenue to be in a range of $510 million to $525 million. Third quarter gross margin is expected to be 33.0-33.5%, operating margin is expected to be above 7%, and adjusted EBITDA margin is expected to be greater than 13%.
Tailwinds
- Travel nurse staffing revenue is expected to be up 3-5% to prior year.
- Language interpretation business has experienced steady growth in billable minutes since May, which we expect will continue through the third quarter
- Third quarter gross margin is expected to be 33.0-33.5%.
- Operating margin is expected to be above 7%.
- Adjusted EBITDA margin is expected to be greater than 13%.
Headwinds
- COVID-19 pandemic has been highly disruptive to economic activity and to healthcare infrastructure
- Healthcare labor demand is volatile.
- Elective procedures and routine care are still below pre-crisis levels.
- Allied revenue is expected to be lower than prior year by 27-29%
- Physician and Leadership Solutions segment revenue estimated at nearly 30% below prior year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
-0.0%
Avg return
Earnings day
-1.9%
Avg return
5 days after
-0.6%
Avg return
30 days after
52%
34 / 66 earnings
Positive
+29.2%
Q1 2026
Best reaction
-29.5%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +29.2% | +38.5% | +41.5% | |
| Q4 2025 | +11.4% | +15.8% | +4.2% | |
| Q3 2025 | -3.4% | -10.0% | -11.8% | |
| Q2 2025 | +2.3% | +10.2% | +23.2% | |
| Q1 2025 | +8.2% | +7.1% | +3.8% | |
| Q4 2024 | +6.7% | +0.5% | -6.8% | |
| Q3 2024 | -29.5% | -36.7% | -36.2% | |
| Q2 2024 | -3.1% | -11.9% | -24.0% | |
| Q1 2024 | -9.3% | +3.4% | -10.1% | |
| Q4 2023 | -20.9% | -25.5% | -24.7% | |
| Q3 2023 | -12.2% | -17.7% | -9.5% | |
| Q2 2023 | -16.4% | -16.6% | -18.6% | |
| Q1 2023 | +7.7% | +10.3% | +18.0% | |
| Q4 2022 | -4.0% | -2.3% | -13.4% | |
| Q3 2022 | -7.5% | -0.4% | +1.7% | |
| Q2 2022 | +1.8% | -1.7% | -12.7% | |
| Q1 2022 | -8.2% | -10.6% | -1.3% | |
| Q4 2021 | +8.8% | +5.3% | +10.4% | |
| Q3 2021 | -8.2% | -1.4% | +3.7% | |
| Q2 2021 | +5.4% | +3.8% | +15.4% | |
| Q1 2021 | +7.6% | +10.3% | +11.0% | |
| Q4 2020 | +4.1% | -0.7% | +1.4% | |
| Q3 2020 | -5.8% | -7.0% | -1.9% | |
| Q2 2020 | +4.8% | -4.5% | -1.7% | |
| Q1 2020 | -9.3% | -12.1% | +13.0% | |
| Q4 2019 | +9.6% | +5.6% | +4.0% | |
| Q3 2019 | -0.5% | +2.1% | +0.8% | |
| Q2 2019 | +7.7% | +11.4% | +15.5% | |
| Q1 2019 | +1.9% | -0.4% | -6.0% | |
| Q4 2018 | -12.5% | -14.7% | -26.7% | |
| Q3 2018 | +13.3% | +11.6% | +23.9% | |
| Q2 2018 | -15.2% | -10.4% | -5.4% | |
| Q1 2018 | -21.9% | -21.6% | -14.6% | |
| Q4 2017 | +4.8% | +4.8% | +10.9% | |
| Q3 2017 | -3.6% | -1.6% | +16.3% | |
| Q2 2017 | +1.1% | +6.9% | +4.4% | |
| Q1 2017 | -6.8% | -6.2% | -9.0% | |
| Q4 2016 | +4.0% | +7.9% | +10.3% | |
| Q3 2016 | -1.6% | -2.7% | -7.8% | |
| Q2 2016 | -11.9% | -13.8% | -13.5% | |
| Q1 2016 | +1.0% | — | — | |
| Q4 2015 | +1.8% | — | — | |
| Q3 2015 | +5.9% | — | — | |
| Q2 2015 | +0.1% | — | — | |
| Q1 2015 | -1.4% | — | — | |
| Q4 2014 | +2.0% | — | — | |
| Q3 2014 | -1.7% | — | — | |
| Q2 2014 | +5.7% | — | — | |
| Q1 2014 | +3.8% | — | — | |
| Q4 2013 | +1.4% | — | — | |
| Q4 2012 | +13.4% | — | — | |
| Q3 2013 | +13.4% | — | — | |
| Q2 2013 | +6.1% | — | — | |
| Q1 2013 | -1.3% | — | — | |
| Q3 2012 | +4.0% | — | — | |
| Q2 2012 | +5.5% | — | — | |
| Q1 2011 | +19.4% | — | — | |
| Q1 2012 | +6.1% | — | — | |
| Q4 2011 | -2.0% | — | — | |
| Q4 2009 | -2.0% | — | — | |
| Q3 2011 | -3.7% | — | — | |
| Q3 2010 | -3.7% | — | — | |
| Q4 2010 | -1.4% | — | — | |
| Q2 2010 | -1.4% | — | — | |
| Q2 2011 | -1.4% | — | — | |
| Q1 2010 | -0.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro